Welcome to Cell & Gene Live – An interactive forum to discuss some of the most important technologies and trends impacting cell and gene therapies.
Throughout the year, our editors sit down with industry experts to discuss how biotechs can tackle some of today’s biggest challenges they may face in driving progress in the cell and gene therapy field. Even better, the audience gets ask questions during the presentation. Each Cell & Gene Live session is archived and can be accessed at any time by registered site users.
FROM BOTTLENECK TO BREAKTHROUGH: REIMAGINING THE MRNA THERAPEUTICS SUPPLY CHAIN
From Bottleneck To Breakthrough: Reimagining The mRNA Therapeutics Supply Chain
The supply chain for mRNA-based cell and gene therapies presents unique challenges due to the sensitive nature of these products. And, as mRNA technology continues to advance, robust processes and scalable solutions are necessary to meet increasing demand.
MODERNIZING CAR-T MANUFACTURING: IS POINT OF CARE THE FUTURE?
Modernizing CAR-T Manufacturing: Is Point Of Care The Future?
While centralized CAR-T manufacturing is the industry standard, some folks believe the future of CAR-T manufacturing will be decentralized, taking place at or near patients’ point of care (POC).
INSIDE NEXT-GEN PLATFORMS FOR CELL THERAPY MANUFACTURING
Inside Next-Gen Platforms For Cell Therapy Manufacturing
With additional cell therapy approvals on the horizon, diverse products and platforms are needed to help ensure safety and efficacy in manufacturing, increase speed to market, and decrease overall CoGS.
TOP STRATEGIES TO REDUCE OFF-TARGET EFFECTS FOR SAFER GENOME EDITING
Top Strategies To Reduce Off-Target Effects For Safer Genome Editing
Genome editing holds immense promise for treating genetic diseases, but off-target effects remain a significant concern resulting in the development of various strategies to reduce those risks.
UNLOCKING THE FUTURE OF ALLOGENEIC CELL THERAPY FOR ONCOLOGY
Unlocking The Future Of Allogeneic Cell Therapy For Oncology
Hear from experts in the cell and gene therapy space about their shared insights into potential trends driving the future of allogeneic therapies for oncology.
STEM-CELL DERIVED THERAPIES: FROM SOURCE TO SITE
Stem-Cell Derived Therapies: From Source To Site
Stem cells are the backbone of many allogeneic, “off-the-shelf” cell therapies. Watch as industry experts discuss questions and considerations regarding stem-cell-derived therapies
HOW-TO-REDUCE-BATCH-TO-BATCH-VARIATION-IN-CELL-THERAPY-MANUFACTURING
How To Reduce Batch-to-Batch Variation In Cell Therapy Manufacturing
As the patient’s immune cells are the starting materials, inherent biological variability leads to CAR-T manufacturing.
2024 REGULATORY OUTLOOK WITH FDA'S DRS. PETER MARKS AND NICOLE VERDUN
2024 Regulatory Outlook With FDA's Drs. Peter Marks And Nicole Verdun
Explore the evolving regulatory landscape for cell and gene therapies in 2024 including the increasing speed availability of cell and gene therapies by enabling manufacturing processes and standards development.
MEET OUR HOSTS
Erin Harris is chief editor of Cell & Gene. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders.
CONSIDERATIONS FOR INVESTING IN YOUR GENE THERAPY'S AUTOMATION FRAMEWORK
Considerations For Investing In Your Gene Therapy's Automation Framework
Deciding which technology to incorporate into your biotech’s operations, such as automation, machine learning, or AI, requires consideration into what's scalable and relevant to your goals.
MRNA FOR CANCER IMMUNOTHERAPY: 2024 OUTLOOK
mRNA For Cancer Immunotherapy: 2024 Outlook
As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS.
ARE WE THERE YET? ROADMAP(S) TO HIGHER QUALITY AAV
Are We There Yet? Roadmap(s) To Higher Quality AAV
Current limitations in AAV gene therapy manufacturing platforms often leave us making difficult tradeoffs. To learn how companies are evaluating and striving to overcome these tradeoffs in their technology and outsourcing partner selections, facility designs, and regulato...
OPTIMIZING YOUR COLD CHAIN FOR CELL THERAPIES
Optimizing Your Cold Chain For Cell Therapies
Cell & Gene’s Chief Editor Erin Harris and expert panelists discuss practical ways to improve shipping systems, tracking, product monitoring, and more for both just-in-time delivery and cryogenic preservation.
STABILITY TO SCALABILITY: THE FUTURE OF VIRAL VECTOR THERAPIES
Stability To Scalability: The Future Of Viral Vector Therapies
Despite advances that have contributed to improvements in viral vector yields, innovation is still needed in the CGT sector to impact product quality and accelerate scale for viral vector production.
REGULATING THE CGT WORKFLOW TO IMPROVE PATIENT SAFETY
Regulating The CGT Workflow To Improve Patient Safety
As regulatory guidelines evolve, and the need to meet accelerated timelines increases, so too does the need for an efficient manufacturing workflow.
DRIVING DOWN COGS: AUTOMATION'S ROLE IN CELL THERAPY MANUFACTURING
Driving Down COGS: Automation's Role In Cell Therapy Manufacturing
Process automation, task automation, and test automation have become crucial components of cell therapy manufacturing. Improve your cell therapy manufacturing costs and scalability via standardization and automation.
MAJOR TRENDS IN NEXT-GEN RNA ENGINEERING
Major Trends In Next-Gen RNA Engineering
From tissue specificity to potency and durability, major trends in RNA are developing as the space continues to evolve at record-breaking speed. In June 2023, Cell & Gene Live welcomed Nathaniel Wang, CEO and Co-Founder, Replicate Bioscience and Sam Deutch, E...
BUILDING AN IN-HOUSE CELL & GENE MANUFACTURING FACILITY BEST PRACTICES LESSONS LEARNED
Building An In-House Cell & Gene Manufacturing Facility: Best Practices & Lessons Learned
Listen in on a panel discussion where cell and gene therapy experts share their experiences in building state-of-the-art manufacturing facilities and offering detailed advice on how your company can do the same.
SCALING CELL THERAPIES PART 2: ESTABLISHING COMPARABILITY IN MANUFACTURING
Scaling Cell Therapies Part 2: Establishing Comparability In Manufacturing
Michael Blackton, SVP, Cell Therapy Manufacturing, DeTIL Development at Nurix Therapeutics and John Lee, SVP, Cell Therapy Manufacturing at Center for Breakthrough Medicines are back with Cell & Gene Live host Erin Harris for Part 2 of our Scaling Cell Therapies serie...
TACKLING CELL AND GENE THERAPIES' TOP 3 REGULATORY IMPEDIMENTS
Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments
Listen in to this expert discussion on problems in the cell and gene therapy industry, specific FDA initiatives to overcome these, broader regulatory trends, and more.
EVALUATING TRANSLATIONAL RESEARCH TOOLS FOR CGTS
Evaluating Translational Research Tools For CGTs
Translational research tools, including biological assays (bioassays) and biological markers (biomarkers), are needed to bridge the gap from understanding the disease process to identifying therapeutic targets and testing potential therapies in preparation for clinical re...
SCALING CELL THERAPIES: AUTO VS. ALLO
Scaling Cell Therapies: Auto vs. Allo
To achieve commercial success, a developed process must be scalable and suitable for a manufacturing environment. The scaling strategy depends on the type of cell therapy.
ADVANCEMENTS IN TARGETED MRNA DELIVERY
Advancements In Targeted mRNA Delivery
mRNA has broad potential as a therapeutic. The clinical translation of mRNA therapeutics has been made possible through advances in the design of mRNA manufacturing and intracellular delivery methods. However, broad application of mRNA is still limited by the need for imp...
WIN THE CGT TALENT FIGHT: HOW TO FIND AND RETAIN EXPERTS
Win The CGT Talent Fight: How To Find And Retain Experts
The cell and gene therapy (CGT) market is expected to be worth $5.5 Billion by 2026. Yet, the sector struggles with recruiting and retaining enough experienced candidates needed to bring life-saving treatments to market. Why is that, and what can you do now to overcome th...
KITE PHARMA'S ULTIMATE SUPPLY CHAIN TEST
Kite Pharma's Ultimate Supply Chain Test - A Q&A With Their 4-Exec Panel On Overcoming The Pandemic's Disruption
Throughout the pandemic, Kite Pharma overcame constantly disrupted supply chains, including limited flights and border closings, all while ensuring that daily shipments of live cells remained on schedule and that the critical needs of people with cancer were met. Four of ...
THE THERAPEUTIC POTENTIAL OF EXOSOMES
The Therapeutic Potential Of Exosomes
In this Cell & Gene Live, Dr. Maria Mitrani, Co-Founder and Chief Scientific Officer at Organicell; Benny Sorensen, Scientific Advisory Board member at Codiak BioScience; and Nicolas Rousseau, Co-Founder and COO at EVerZom talk to Chief Editor Erin Harris about the se...
THE FUTURE OF CRISPR-ENGINEERED STEM CELL THERAPIES
The Future of CRISPR-Engineered Stem Cell Therapies
To learn more about CRISPR gene editing, Cell and Gene Chief Editor, Erin Harris, sat down with Sadik Kassim, Chief Technical Officer at Vor Biopharma to discuss the benefits of CRISPR-engineered stem cell therapies, the challenges and feasible solutions, what’s nex...
CAN INNOVATION DRIVE DOWN CELL THERAPY MANUFACTURING COSTS?
Can Innovation Drive Down Cell Therapy Manufacturing Costs?
The high cost of producing new cell and gene therapies is one of the largest issues facing the industry. After launching Kymriah and Yescarta, Novartis’ price tags were $475,000 and $375,000, respectively. Advancements in manufacturing are driving costs down, but no...
